EA201700155A1 - PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS - Google Patents
PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSISInfo
- Publication number
- EA201700155A1 EA201700155A1 EA201700155A EA201700155A EA201700155A1 EA 201700155 A1 EA201700155 A1 EA 201700155A1 EA 201700155 A EA201700155 A EA 201700155A EA 201700155 A EA201700155 A EA 201700155A EA 201700155 A1 EA201700155 A1 EA 201700155A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- tuberculosis
- treatment
- pharmaceutical composition
- drugs
- auxiliary agent
- Prior art date
Links
- 201000008827 tuberculosis Diseases 0.000 title abstract 8
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 abstract 3
- 239000012752 auxiliary agent Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 abstract 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229940121383 antituberculosis agent Drugs 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 235000019253 formic acid Nutrition 0.000 abstract 1
- 235000012907 honey Nutrition 0.000 abstract 1
- 229960004903 invert sugar Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000010355 oscillation Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000007086 side reaction Methods 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 239000000814 tuberculostatic agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к области фармацевтики, конкретно к фармацевтической композиции противотуберкулезных препаратов для лечения туберкулеза, в том числе множественно лекарственно устойчивого туберкулеза (МЛУ-ТБ). Техническим результатом является повышение эффективности лечения больных туберкулезом, снижение токсичности, дозировки и количества наименования применяемых препаратов, сокращение сроков лечения с устранением вредных побочных реакций применяемых препаратов. Это достигается тем, что в известную фармацевтическую композицию для лечения туберкулеза, содержащую в своем составе по меньшей мере два активных противотуберкулезных агента из первого и второго ряда, а также фармацевтически приемлемые наполнители, дезинтегранты, опудривающие вещества, предлагается дополнительно вводить вспомогательный агент, представляющий собой обработанную электромагнитными колебаниями с частотой 10-3000 Гц смесь, приготовленную на основе сахара, меда, инвертированного сахара, натрия цитрата, муравьиной кислоты и левулиновой кислоты при следующем соотношении компонентов: 1:1:0,04:0,04:0,04:0,04-1:1:700:200:40:200. Вспомогательный агент используется в сиропообразном виде. Использование заявленной группы фармацевтической композиции обеспечивает высокий терапевтический эффект при лечении туберкулеза, в том числе множественно лекарственно устойчивого туберкулеза.The invention relates to the field of pharmaceuticals, specifically to the pharmaceutical composition of anti-TB drugs for the treatment of tuberculosis, including multidrug-resistant tuberculosis (MDR-TB). The technical result is to increase the efficiency of treatment of patients with tuberculosis, reduce toxicity, dosage and quantity of the name of the drugs used, reduce the time of treatment with the elimination of harmful side reactions of the drugs used. This is achieved by the fact that in a known pharmaceutical composition for treating tuberculosis, containing at least two active anti-tuberculosis agents from the first and second row, as well as pharmaceutically acceptable excipients, disintegrants, powders, it is proposed to additionally introduce an auxiliary agent that is treated electromagnetic oscillations with a frequency of 10-3000 Hz mixture prepared on the basis of sugar, honey, invert sugar, sodium citrate, formic acid and l vulinovoy acid in the following ratio: 1: 1: 0.04: 0.04: 0.04: 0,04-1: 1: 700: 200: 40: 200. The auxiliary agent is used in a syrup-like form. The use of the claimed group of the pharmaceutical composition provides a high therapeutic effect in the treatment of tuberculosis, including multidrug-resistant tuberculosis.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KZ20141353 | 2014-10-20 | ||
| PCT/KZ2015/000021 WO2016099233A2 (en) | 2014-10-20 | 2015-10-16 | Pharmaceutical composition for treating tuberculosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201700155A1 true EA201700155A1 (en) | 2017-10-31 |
Family
ID=56127805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201700155A EA201700155A1 (en) | 2014-10-20 | 2015-10-16 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS |
Country Status (2)
| Country | Link |
|---|---|
| EA (1) | EA201700155A1 (en) |
| WO (1) | WO2016099233A2 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1001869A3 (en) * | 1988-10-12 | 1990-04-03 | Franz Legros | METHOD OF PACKAGING liposomal AMINOGLUCOSIDIQUES ANTIBIOTICS IN PARTICULAR THE GENTAMYCIN. |
| DE19754082A1 (en) * | 1997-12-05 | 1999-06-10 | Knoll Ag | Method of combating obesity |
| RU2221583C2 (en) * | 2002-02-04 | 2004-01-20 | Марков Геннадий Александрович | Composition with curative-prophylactic effect |
| MX2011002348A (en) * | 2008-09-03 | 2011-06-27 | Pfizer | Combination therapy for tuberculosis. |
| US20110268809A1 (en) * | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
-
2015
- 2015-10-16 WO PCT/KZ2015/000021 patent/WO2016099233A2/en not_active Ceased
- 2015-10-16 EA EA201700155A patent/EA201700155A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016099233A2 (en) | 2016-06-23 |
| WO2016099233A3 (en) | 2016-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202090955A1 (en) | METHODS OF USING EHMT2 INHIBITORS IN TREATMENT OR PREVENTION OF BLOOD DISORDERS | |
| MX393855B (en) | COMBINATION THERAPY INCLUDING A RAF INHIBITOR AND TRAMETINIB | |
| RU2013136378A (en) | APPLICATION OF PHYTOCANNABINOID CANNABIDIOL (CBD) IN COMBINATION WITH STANDARD ANTIEPILEPTIC DEDICATION (SAED) FOR THE TREATMENT OF EPILEPSY | |
| EA201590166A8 (en) | COMBINED THERAPY FOR THE TREATMENT OF SCATTERED SCLEROSIS | |
| EA202090573A1 (en) | COMPOSITIONS OF NIRAPARIBA | |
| EA201490279A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| EA201992162A1 (en) | COMPOSITIONS BASED ON NIRAPARIB | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| NI201100147A (en) | METHODS TO TREAT ACUTE MYOCARDIAL INFARCTIONS AND RELATED DISORDERS. | |
| RU2017134443A (en) | METHOD OF TREATMENT WITH USE OF TRADIPTANT | |
| EA201490163A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
| RU2017120184A (en) | DRUGS TO DELAY THE COURSE OF PARKINSON'S DISEASE | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
| FI3352735T3 (en) | Sustained release olanzapine formulations | |
| MX2020005006A (en) | Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder. | |
| HRP20240812T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
| MX2015013115A (en) | NEW DOSAGE REGIMES OF CELGOSIVIR FOR THE TREATMENT OF DENGUE. | |
| RU2020120156A (en) | TREATMENT AND LOSS OF BONE TISSUE CAUSED BY ANDROGENIC DEPRIVATION THERAPY USING CIS-CLOMIFEN | |
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
| MX391191B (en) | EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS. | |
| EA201700155A1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TUBERCULOSIS | |
| AR101227A1 (en) | COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN |